GSK (GSK) announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease.  Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease (LRTD) caused by RSV. With the latest approval, Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.In the United St ...